Iovance Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary

Iovance Biotherapeutics

08/08/2023 23:01

* Iovance Biotherapeutics Inc  IOVA.OQ  reported a quarterly
adjusted loss of 47 cents​​ per share for the quarter ended in
June. The mean expectation of thirteen analysts for the quarter
was for a loss of 80 cents per share.
    * Revenue was $238.00 thousand​; analysts expected $3.58
million. 
    * Iovance Biotherapeutics Inc's reported EPS for the quarter
was a
loss of 47 cents​.
    * The mean earnings estimate of analysts had fallen by
about 29%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Iovance Biotherapeutics Inc shares had risen by 0.1% this
quarter and gained 10.3% so far this year.
    * The company reported a quarterly loss of $106.53 million.
    * Wall Street's median 12-month price target for Iovance
Biotherapeutics Inc is $23.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 10:01 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.80          -0.47          Beat
 Mar. 31 2023      -0.74          -0.50          Beat
 Dec. 31 2022      -0.64          -0.64          Met
 Sep. 30 2022      -0.64          -0.63          Beat